{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:20:11Z","timestamp":1785522011484,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a cardiovascular risk\u2013enhancing condition. Its prognostic significance following PCI in non-diabetic adults, and the temporal distribution of that risk, remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate whether coded steatotic liver disease is associated with adverse one-year post-PCI outcomes in non-diabetic adults, and to characterize the temporal concentration of risk across early (day 0\u201330) and late (day 31\u2013365) post-procedural periods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective cohort study using the TriNetX US Collaborative Network (2014\u20132023). Non-diabetic adults undergoing PCI were stratified by steatotic liver disease (SLD) status (ICD-10-CM K76.0 and\/or K75.81). Primary outcome: all-cause mortality (day 1\u2013365). Secondary outcomes: heart failure, MI, 3-point MACE, cardiogenic shock, cardiac arrest, and bleeding. PSM (1:1) balanced demographics, cardiometabolic comorbidities, ACS type, and medications. Outcomes were further assessed across prespecified early and late windows.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After PSM, 7,434 patients per group were well balanced (SMD\u2009&lt;\u20090.10). All-cause mortality did not differ significantly (2.8% vs. 3.1%; HR, 0.93; 95% CI, 0.77\u20131.13;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.472). SLD was significantly associated with higher one-year rates of incident heart failure (10.1% vs. 8.9%; HR, 1.15; 95% CI, 1.02\u20131.30;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027) and bleeding events (5.1% vs. 3.8%; HR, 1.35; 95% CI, 1.15\u20131.59;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Time-stratified analysis showed that cardiogenic shock risk was concentrated in the first 30 days (RR, 1.45;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and attenuated to null beyond 30 days and overall. Heart failure excess was similarly early-driven (RR, 1.17;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), but the overall one-year signal remained significant (HR, 1.15;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027), reflecting the sustained contribution of early events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among non-diabetic adults undergoing PCI, coded steatotic liver disease is associated with significantly higher one-year rates of heart failure and bleeding, without a significant mortality difference. Hemodynamic vulnerability is concentrated in the early peri-procedural period, while hemorrhagic risk is sustained. These findings support heightened early surveillance and individualized antithrombotic planning for SLD patients undergoing PCI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-06017-y","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:12:55Z","timestamp":1779693175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of coded steatotic liver disease on outcomes of percutaneous coronary intervention in non-diabetic adults: insights from a multicenter real-world cohort"],"prefix":"10.1186","volume":"26","author":[{"given":"Yussif","family":"Issaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Maraqah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didien","family":"Meyahnwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Adjei-Sefah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efeturi","family":"Okorigba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miracle","family":"Oparah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarpong","family":"Boateng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakeemah","family":"Abdul-Kareem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayowa","family":"Adefuye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy Loic","family":"Nguefang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basile","family":"Njei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Zarich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"6017_CR1","doi-asserted-by":"publisher","first-page":"1609071","DOI":"10.3389\/fcvm.2025.1609071","volume":"12","author":"JJ Gries","year":"2025","unstructured":"Gries JJ, Hassan Virk HU, Wang Z, et al. Outcomes of Coronary Revascularization in Patients with MASLD: A Systematic Review. Front Cardiovasc Med. 2025;12:1609071.","journal-title":"Front Cardiovasc Med"},{"key":"6017_CR2","doi-asserted-by":"crossref","unstructured":"Nasiri-Ansari N, Androutsakos T, Flessa CM et al. Endothelial Cell Dysfunction and NAFLD: A Concise Review. Cells. 2022;11(16).","DOI":"10.3390\/cells11162511"},{"issue":"4","key":"6017_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of NAFLD and NASH: a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"issue":"1","key":"6017_CR4","doi-asserted-by":"publisher","first-page":"33386","DOI":"10.1038\/srep33386","volume":"6","author":"S Wu","year":"2016","unstructured":"Wu S, Wu F, Ding Y, et al. Association of NAFLD with major adverse cardiovascular events. Sci Rep. 2016;6(1):33386.","journal-title":"Sci Rep"},{"issue":"12","key":"6017_CR5","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809\u2013e281728.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"6017_CR6","doi-asserted-by":"publisher","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le P, Tatar M, Dasarathy S, et al. Estimated Burden of MASLD in US Adults, 2020 to 2050. JAMA Netw Open. 2025;8(1):e2454707.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"6017_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702.","journal-title":"Gut"},{"key":"6017_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng H, Sechi LA, Navarese EP, et al. MASLD and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23:346.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"6017_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G, et al. NAFLD and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903\u201313.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"6017_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, et al. NAFLD and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589\u2013600.","journal-title":"J Hepatol"},{"issue":"6","key":"6017_CR11","first-page":"867","volume":"124","author":"L Sun","year":"2011","unstructured":"Sun L, L\u00fc SZ. Association between NAFLD and coronary artery disease severity. Chin Med J (Engl). 2011;124(6):867\u201372.","journal-title":"Chin Med J (Engl)"},{"issue":"8","key":"6017_CR12","first-page":"e89355","volume":"17","author":"NK Bhatt","year":"2025","unstructured":"Bhatt NK, Agarwal Y, Neelakantan Ramaswamy S, et al. NAFLD\/MASLD fueling cardiovascular risk: systematic review. Cureus. 2025;17(8):e89355.","journal-title":"Cureus"},{"key":"6017_CR13","doi-asserted-by":"publisher","first-page":"101153","DOI":"10.1016\/j.lanepe.2024.101153","volume":"48","author":"J Boeckmans","year":"2025","unstructured":"Boeckmans J, Prochaska JH, Gieswinkel A, et al. Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without MASLD. Lancet Reg Health Eur. 2025;48:101153.","journal-title":"Lancet Reg Health Eur"},{"issue":"7","key":"6017_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","volume":"15","author":"QM Anstee","year":"2018","unstructured":"Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with NAFLD. Nat Rev Gastroenterol Hepatol. 2018;15(7):425\u201339.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"6017_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/liv.15801","volume":"44","author":"J Boeckmans","year":"2024","unstructured":"Boeckmans J, Sandrin L, Knackstedt C, Schattenberg JM. Liver stiffness as a cornerstone in heart disease risk assessment. Liver Int. 2024;44(2):344\u201356.","journal-title":"Liver Int"},{"issue":"2","key":"6017_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hep.20781","volume":"42","author":"N Villanova","year":"2005","unstructured":"Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in NAFLD. Hepatology. 2005;42(2):473\u201380.","journal-title":"Hepatology"},{"issue":"6","key":"6017_CR17","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/j.1572-0241.2007.01774.x","volume":"103","author":"A Wieckowska","year":"2008","unstructured":"Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating IL-6 levels in human NASH. Am J Gastroenterol. 2008;103(6):1372\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"6017_CR18","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.2337\/dc07-1088","volume":"30","author":"AMG Cali","year":"2007","unstructured":"Cali AMG, Zern TL, Taksali SE, et al. Intrahepatic fat accumulation and lipoprotein composition in obese adolescents. Diabetes Care. 2007;30(12):3093\u20138.","journal-title":"Diabetes Care"},{"key":"6017_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.hrtlng.2022.04.010","volume":"55","author":"J Guan","year":"2022","unstructured":"Guan J, Li X, Gong S, Li L. Impact of diabetes mellitus on PCI outcomes for chronic total occlusions. Heart Lung. 2022;55:108\u201316.","journal-title":"Heart Lung"},{"issue":"3","key":"6017_CR20","first-page":"e61","volume":"19","author":"K Ogunniyi","year":"2025","unstructured":"Ogunniyi K, Ugwendum D, Mestarihi A, et al. Outcomes of PCI among patients with MASLD: A nationwide study. J Clin Lipidol. 2025;19(3):e61\u20132.","journal-title":"J Clin Lipidol"},{"issue":"8","key":"6017_CR21","first-page":"e17338","volume":"13","author":"H Ali","year":"2021","unstructured":"Ali H, Kazmi M, Choi C, et al. In-Hospital Outcomes of Patients With NAFLD Who Underwent PCI. Cureus. 2021;13(8):e17338.","journal-title":"Cureus"},{"issue":"1","key":"6017_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","volume":"17","author":"M Alexander","year":"2019","unstructured":"Alexander M, Loomis AK, van der Lei J, et al. Risks and clinical predictors of cirrhosis and HCC in adults with NAFLD: real-world study of 18 million patients. BMC Med. 2019;17(1):95.","journal-title":"BMC Med"},{"issue":"3","key":"6017_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.14366\/usg.24219","volume":"44","author":"X Jin","year":"2025","unstructured":"Jin X, Yip TCF, Wong GLH, et al. The new definition of MASLD: the role of ultrasound and elastography. Ultrasonography. 2025;44(3):189\u2013201.","journal-title":"Ultrasonography"},{"issue":"22","key":"6017_CR24","doi-asserted-by":"publisher","first-page":"e035371","DOI":"10.1161\/JAHA.123.035371","volume":"13","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang HJ, Fang CC, et al. Association Between Noninvasive Liver Fibrosis Scores and Heart Failure in a General Population. J Am Heart Assoc. 2024;13(22):e035371.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"6017_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00392-022-02078-z","volume":"112","author":"FG Biccir\u00e8","year":"2023","unstructured":"Biccir\u00e8 FG, Barill\u00e0 F, Sammartini E, et al. Relationship between non-invasively detected liver fibrosis and in-hospital outcomes in ACS patients undergoing PCI. Clin Res Cardiol. 2023;112(2):236\u201346.","journal-title":"Clin Res Cardiol"},{"key":"6017_CR26","doi-asserted-by":"publisher","first-page":"e1051","DOI":"10.4244\/EIJ-D-24-00992","volume":"21","author":"DS Castiello","year":"2025","unstructured":"Castiello DS, Oliva A, And\u00f2 G, et al. Antithrombotic therapy in complex percutaneous coronary intervention. EuroIntervention. 2025;21:e1051\u201368.","journal-title":"EuroIntervention"},{"key":"6017_CR27","doi-asserted-by":"publisher","unstructured":"Forzano I, Narciso V, Canonico ME, et al. Optimal Medical Therapy Targeting Metabolic Status for Secondary Prevention in Patients Undergoing PCI. J Clin Med. 2026;15:1108. https:\/\/doi.org\/10.3390\/jcm15031108.","DOI":"10.3390\/jcm15031108"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06017-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06017-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06017-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:09:01Z","timestamp":1785517741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06017-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6017"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06017-y","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted using de-identified electronic health record data obtained from the TriNetX U.S. Collaborative Network. TriNetX data are fully de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule (45 CFR \u00a7\u00a0164.514[a]).In accordance with U.S. federal regulations governing human subjects research (45 CFR \u00a7 46), studies involving secondary analysis of de-identified data do not constitute human subjects research and are exempt from institutional review board (IRB) review and informed consent requirements.The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"643"}}